Gordin A, Kalima S, Mäkelä P, Antikainen R
Scand J Infect Dis. 1987;19(1):97-102. doi: 10.3109/00365548709032384.
132 female hospital employees (mean age 32 years) with uncomplicated, bacteriologically verified acute lower urinary tract infection were included in a randomized study. The patients were treated for 3 or 10 days with a sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. or for 3 or 10 days with pivmecillinam (500 mg) t.i.d. The first follow-up evaluation was performed 3-5 days after the treatment. In both sulfadiazine-trimethoprim groups the cure rate was 97% and in both pivmecillinam groups 80%. This difference was mainly due to the occurrence of pivmecillinam-resistant Staphylococcus saprophyticus strains. 109 patients attended the second follow-up visit about 4 weeks after treatment. The prevalences of reinfections and relapses were 18% in both 3-day regimens and 4-7% in both 10-day regimens. No side-effects were reported in the 3-day sulfadiazine-trimethoprim group, while about 20% in the corresponding 10-day group had side-effects. Side-effects were not common in patients treated with pivmecillinam.
132名无并发症、经细菌学证实为急性下尿路感染的女性医院员工（平均年龄32岁）被纳入一项随机研究。患者接受磺胺嘧啶-甲氧苄啶组合（500毫克+150毫克）每日两次治疗3天或10天，或接受匹美西林（500毫克）每日三次治疗3天或10天。首次随访评估在治疗后3至5天进行。在两个磺胺嘧啶-甲氧苄啶组中治愈率均为97%，在两个匹美西林组中均为80%。这种差异主要是由于耐匹美西林的腐生葡萄球菌菌株的出现。109名患者在治疗后约4周参加了第二次随访。在两种3天治疗方案中，再感染和复发的发生率均为18%，在两种10天治疗方案中均为4-7%。在3天磺胺嘧啶-甲氧苄啶组中未报告有副作用，而在相应的10天组中约20%有副作用。接受匹美西林治疗的患者中副作用不常见。
